View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest Events9 Meters Biopharma 향후 성장Future 기준 점검 2/69 Meters Biopharma (는) 각각 연간 41.4% 및 56.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 39.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -185.6% 로 예상됩니다.핵심 정보41.4%이익 성장률39.93%EPS 성장률Pharmaceuticals 이익 성장19.0%매출 성장률56.6%향후 자기자본이익률-185.62%애널리스트 커버리지Low마지막 업데이트30 May 2023최근 향후 성장 업데이트Price Target Changed • May 26Price target decreased by 43% to US$10.25Down from US$17.93, the current price target is an average from 4 analysts. New target price is 1,215% above last closing price of US$0.78. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$3.45 next year compared to a net loss per share of US$3.38 last year.Major Estimate Revision • May 22Consensus EPS estimates fall by 43%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$2.41 to -US$3.45 per share. Revenue forecast of US$2.08m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income decline 17% next year. Consensus price target broadly unchanged at US$17.69. Share price rose 6.2% to US$0.77 over the past week.Price Target Changed • Mar 23Price target decreased by 32% to US$22.68Down from US$33.12, the current price target is an average from 4 analysts. New target price is 1,631% above last closing price of US$1.31. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$3.26 next year compared to a net loss per share of US$3.03 last year.Price Target Changed • Mar 17Price target increased by 18% to US$39.20Up from US$33.12, the current price target is an average from 5 analysts. New target price is 2,741% above last closing price of US$1.38. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$3.33 next year compared to a net loss per share of US$3.03 last year.Price Target Changed • Feb 14Price target decreased by 15% to US$33.12Down from US$38.80, the current price target is an average from 6 analysts. New target price is 1,433% above last closing price of US$2.16. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$3.33 next year compared to a net loss per share of US$3.03 last year.Price Target Changed • Nov 03Price target decreased to US$57.00Down from US$68.00, the current price target is an average from 5 analysts. New target price is 2,153% above last closing price of US$2.53. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$3.40 next year compared to a net loss per share of US$3.03 last year.모든 업데이트 보기Recent updates공고 • Jun 189 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price RuleOn June 12, 2023, 9 Meters Biopharma, Inc. was notified by the Nasdaq Stock Market LLC (‘Nasdaq’) that for the last 31 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the ‘Bid Price Rule’). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until December 11, 2023, to regain compliance with the Bid Price Rule. If at any time before December 11, 2023, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with a written confirmation of compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule by December 11, 2023, the Company may be eligible for an additional 180-day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the Bid Price Rule, and would need to provide written notice of its intention to cure the bid price deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not regain compliance with the Bid Price Rule when required, Nasdaq will provide written notification to the Company that its common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq hearings panel. The notice from Nasdaq has no immediate effect on the listing of the Company’s common stock and its common stock will continue to be listed on the Nasdaq Capital Market under the symbol ‘NMTR’. The Company is currently evaluating its options for regaining compliance. There can be no assurance that the Company will regain compliance with the Bid Price Rule or maintain compliance with any of the other Nasdaq continued listing requirements.공고 • Jun 019 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO9 Meters Biopharma, Inc. board of directors appointed Chief Financial Officer Bethany Sensenig to serve as interim CEO. Sensenig will maintain her CFO role. Sensenig joined 9 Meters in January 2022after three years as CFO and head of U.S. operations for Minovia Therapeutics, a clinical-stage biotech. She previously served in various roles at the pharma giants Biogen and Merck & Co.공고 • May 31+ 2 more updates9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President9 Meters Biopharma, Inc. announced that the Board of Directors has accepted the resignation of John Temperato as President of the Company effective immediately.Price Target Changed • May 26Price target decreased by 43% to US$10.25Down from US$17.93, the current price target is an average from 4 analysts. New target price is 1,215% above last closing price of US$0.78. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$3.45 next year compared to a net loss per share of US$3.38 last year.Major Estimate Revision • May 22Consensus EPS estimates fall by 43%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$2.41 to -US$3.45 per share. Revenue forecast of US$2.08m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income decline 17% next year. Consensus price target broadly unchanged at US$17.69. Share price rose 6.2% to US$0.77 over the past week.Price Target Changed • Mar 23Price target decreased by 32% to US$22.68Down from US$33.12, the current price target is an average from 4 analysts. New target price is 1,631% above last closing price of US$1.31. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$3.26 next year compared to a net loss per share of US$3.03 last year.Price Target Changed • Mar 17Price target increased by 18% to US$39.20Up from US$33.12, the current price target is an average from 5 analysts. New target price is 2,741% above last closing price of US$1.38. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$3.33 next year compared to a net loss per share of US$3.03 last year.Price Target Changed • Feb 14Price target decreased by 15% to US$33.12Down from US$38.80, the current price target is an average from 6 analysts. New target price is 1,433% above last closing price of US$2.16. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$3.33 next year compared to a net loss per share of US$3.03 last year.Board Change • Nov 16High number of new and inexperienced directorsThere are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. 1 experienced director. No highly experienced directors. Independent Director Lorin Johnson is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Price Target Changed • Nov 03Price target decreased to US$57.00Down from US$68.00, the current price target is an average from 5 analysts. New target price is 2,153% above last closing price of US$2.53. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$3.40 next year compared to a net loss per share of US$3.03 last year.Seeking Alpha • Oct 179 Meters Biopharma to execute 1-for-20 reverse stock splitClinical-stage company 9 Meters Biopharma (NASDAQ:NMTR) is set to execute a 1-for-20 reverse stock split, effective Oct. 17 5:00 p.m. ET. The company will begin trading on a split-adjusted basis from Oct. 18 under the existing ticker symbol NMTR. The move, which reduces the number of issued and outstanding common shares from 259,107,380 to ~12,955,369, is likely to bring the company into compliance with Nasdaq's minimum bid price requirement. The reverse stock split was previously approved by the company's shareholders at the Jun. 22 annual meeting. The split is not expected to alter any stockholder's percentage interest in the company's equity. NMTR shares were trading -4.53% pre-market. Source: Press ReleasePrice Target Changed • Sep 27Price target increased to US$3.40Up from US$3.00, the current price target is an average from 6 analysts. New target price is 1,487% above last closing price of US$0.21. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.17 next year compared to a net loss per share of US$0.15 last year.Seeking Alpha • Aug 159 Meters Biopharma GAAP EPS of -$0.04 in-line9 Meters Biopharma press release (NASDAQ:NMTR): Q2 GAAP EPS of -$0.04 in-line. As of June 30, 2022, the company's cash and cash equivalents totaled approximately $29.5M, compared to approximately $37.2M as of March 31, 2022.Price Target Changed • Jun 21Price target decreased to US$3.33Down from US$4.33, the current price target is an average from 6 analysts. New target price is 1,049% above last closing price of US$0.29. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$0.17 next year compared to a net loss per share of US$0.15 last year.Recent Insider Transactions • May 20Independent Chairman recently bought US$50k worth of stockOn the 18th of May, Mark Sirgo bought around 106k shares on-market at roughly US$0.47 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$56k. Mark has been a buyer over the last 12 months, purchasing a net total of US$293k worth in shares.Board Change • Apr 27High number of new and inexperienced directorsThere are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. 1 experienced director. No highly experienced directors. Independent Director Lorin Johnson is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • Mar 06President recently bought US$56k worth of stockOn the 3rd of March, John Temperato bought around 100k shares on-market at roughly US$0.56 per share. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of US$134k worth in shares.Price Target Changed • Jan 26Price target decreased to US$4.33Down from US$4.92, the current price target is an average from 5 analysts. New target price is 478% above last closing price of US$0.75. Stock is down 37% over the past year. The company is forecast to post a net loss per share of US$0.15 next year compared to a net loss per share of US$0.58 last year.Recent Insider Transactions • Nov 21President recently bought US$53k worth of stockOn the 18th of November, John Temperato bought around 50k shares on-market at roughly US$1.05 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$100k. John has been a buyer over the last 12 months, purchasing a net total of US$79k worth in shares.Recent Insider Transactions • Nov 21President recently bought US$53k worth of stockOn the 18th of November, John Temperato bought around 50k shares on-market at roughly US$1.05 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$100k. John has been a buyer over the last 12 months, purchasing a net total of US$79k worth in shares.Recent Insider Transactions • Sep 09Independent Chairman recently bought US$100k worth of stockOn the 7th of September, Mark Sirgo bought around 74k shares on-market at roughly US$1.36 per share. This was the largest purchase by an insider in the last 3 months. Mark has been a buyer over the last 12 months, purchasing a net total of US$224k worth in shares.Executive Departure • Jun 26Director Sandeep Laumas has left the companyOn the 22nd of June, Sandeep Laumas was replaced as CEO by John Temperato after 1.2 years in the role. As of March 2021, Sandeep still personally held 60.40k shares (US$71k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.92 years, which is considered inexperienced in the Simply Wall St Risk Model. Under Sandeep's leadership, the company delivered a total shareholder return of -63%.Breakeven Date Change • May 15Forecast to breakeven in 2024The 3 analysts covering 9 Meters Biopharma expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$15.1m in 2024. Average annual earnings growth of 60% is required to achieve expected profit on schedule.Executive Departure • Feb 17Independent Director has left the companyOn the 12th of February, Nissim Darvish's tenure as Independent Director ended after less than a year in the role. We don't have any record of a personal shareholding under Nissim's name. A total of 4 executives have left over the last 12 months.Is New 90 Day High Low • Feb 02New 90-day high: US$1.50The company is up 128% from its price of US$0.66 on 03 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$33.37 per share.Is New 90 Day High Low • Jan 07New 90-day high: US$1.37The company is up 69% from its price of US$0.81 on 08 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$29.56 per share.Is New 90 Day High Low • Nov 17New 90-day high: US$0.89The company is up 6.0% from its price of US$0.84 on 19 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 03New 90-day high: US$0.85The company is up 33% from its price of US$0.64 on 02 July 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.이익 및 매출 성장 예측NasdaqCM:NMTR - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2025N/A-43N/AN/A212/31/2024N/A-41N/AN/A312/31/20233-43N/AN/A43/31/2023N/A-46-37-37N/A12/31/2022N/A-44-37-37N/A9/30/2022N/A-41-35-35N/A6/30/2022N/A-46-36-34N/A3/31/2022N/A-43-36-33N/A12/31/2021N/A-37-32-29N/A9/30/2021N/A-32-30-28N/A6/30/2021N/A-27-24-24N/A3/31/2021N/A-63-26-23N/A12/31/2020N/A-61-23-19N/A9/30/2020N/A-65-19-16N/A6/30/2020N/A-66-19-16N/A3/31/2020N/A-26-16-16N/A12/31/2019N/A-27-18-18N/A9/30/2019N/A-22-17-17N/A6/30/2019N/A-14-17-17N/A3/31/2019N/A-14-12-12N/A12/31/2018N/A-24-15-15N/A9/30/2018N/A-22-15-15N/A6/30/2018N/A-24-12-12N/A3/31/2018N/A-23-11-11N/A12/31/2017N/A-12-5-5N/A9/30/2017N/A-11-4-4N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: NMTR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: NMTR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: NMTR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: NMTR 의 수익(연간 56.6%)이 US 시장(연간 12.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: NMTR 의 수익(연간 56.6%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: NMTR는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/07/18 09:41종가2023/07/18 00:00수익2023/03/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스9 Meters Biopharma, Inc.는 11명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gary NachmanBMO Capital Markets Equity Researchnull nullBMO Capital Markets Equity ResearchKumaraguru RajaBrookline Capital Markets8명의 분석가 더 보기
Price Target Changed • May 26Price target decreased by 43% to US$10.25Down from US$17.93, the current price target is an average from 4 analysts. New target price is 1,215% above last closing price of US$0.78. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$3.45 next year compared to a net loss per share of US$3.38 last year.
Major Estimate Revision • May 22Consensus EPS estimates fall by 43%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$2.41 to -US$3.45 per share. Revenue forecast of US$2.08m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income decline 17% next year. Consensus price target broadly unchanged at US$17.69. Share price rose 6.2% to US$0.77 over the past week.
Price Target Changed • Mar 23Price target decreased by 32% to US$22.68Down from US$33.12, the current price target is an average from 4 analysts. New target price is 1,631% above last closing price of US$1.31. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$3.26 next year compared to a net loss per share of US$3.03 last year.
Price Target Changed • Mar 17Price target increased by 18% to US$39.20Up from US$33.12, the current price target is an average from 5 analysts. New target price is 2,741% above last closing price of US$1.38. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$3.33 next year compared to a net loss per share of US$3.03 last year.
Price Target Changed • Feb 14Price target decreased by 15% to US$33.12Down from US$38.80, the current price target is an average from 6 analysts. New target price is 1,433% above last closing price of US$2.16. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$3.33 next year compared to a net loss per share of US$3.03 last year.
Price Target Changed • Nov 03Price target decreased to US$57.00Down from US$68.00, the current price target is an average from 5 analysts. New target price is 2,153% above last closing price of US$2.53. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$3.40 next year compared to a net loss per share of US$3.03 last year.
공고 • Jun 189 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price RuleOn June 12, 2023, 9 Meters Biopharma, Inc. was notified by the Nasdaq Stock Market LLC (‘Nasdaq’) that for the last 31 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the ‘Bid Price Rule’). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until December 11, 2023, to regain compliance with the Bid Price Rule. If at any time before December 11, 2023, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with a written confirmation of compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule by December 11, 2023, the Company may be eligible for an additional 180-day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the Bid Price Rule, and would need to provide written notice of its intention to cure the bid price deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not regain compliance with the Bid Price Rule when required, Nasdaq will provide written notification to the Company that its common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq hearings panel. The notice from Nasdaq has no immediate effect on the listing of the Company’s common stock and its common stock will continue to be listed on the Nasdaq Capital Market under the symbol ‘NMTR’. The Company is currently evaluating its options for regaining compliance. There can be no assurance that the Company will regain compliance with the Bid Price Rule or maintain compliance with any of the other Nasdaq continued listing requirements.
공고 • Jun 019 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO9 Meters Biopharma, Inc. board of directors appointed Chief Financial Officer Bethany Sensenig to serve as interim CEO. Sensenig will maintain her CFO role. Sensenig joined 9 Meters in January 2022after three years as CFO and head of U.S. operations for Minovia Therapeutics, a clinical-stage biotech. She previously served in various roles at the pharma giants Biogen and Merck & Co.
공고 • May 31+ 2 more updates9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President9 Meters Biopharma, Inc. announced that the Board of Directors has accepted the resignation of John Temperato as President of the Company effective immediately.
Price Target Changed • May 26Price target decreased by 43% to US$10.25Down from US$17.93, the current price target is an average from 4 analysts. New target price is 1,215% above last closing price of US$0.78. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$3.45 next year compared to a net loss per share of US$3.38 last year.
Major Estimate Revision • May 22Consensus EPS estimates fall by 43%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$2.41 to -US$3.45 per share. Revenue forecast of US$2.08m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income decline 17% next year. Consensus price target broadly unchanged at US$17.69. Share price rose 6.2% to US$0.77 over the past week.
Price Target Changed • Mar 23Price target decreased by 32% to US$22.68Down from US$33.12, the current price target is an average from 4 analysts. New target price is 1,631% above last closing price of US$1.31. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$3.26 next year compared to a net loss per share of US$3.03 last year.
Price Target Changed • Mar 17Price target increased by 18% to US$39.20Up from US$33.12, the current price target is an average from 5 analysts. New target price is 2,741% above last closing price of US$1.38. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$3.33 next year compared to a net loss per share of US$3.03 last year.
Price Target Changed • Feb 14Price target decreased by 15% to US$33.12Down from US$38.80, the current price target is an average from 6 analysts. New target price is 1,433% above last closing price of US$2.16. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$3.33 next year compared to a net loss per share of US$3.03 last year.
Board Change • Nov 16High number of new and inexperienced directorsThere are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. 1 experienced director. No highly experienced directors. Independent Director Lorin Johnson is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Price Target Changed • Nov 03Price target decreased to US$57.00Down from US$68.00, the current price target is an average from 5 analysts. New target price is 2,153% above last closing price of US$2.53. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$3.40 next year compared to a net loss per share of US$3.03 last year.
Seeking Alpha • Oct 179 Meters Biopharma to execute 1-for-20 reverse stock splitClinical-stage company 9 Meters Biopharma (NASDAQ:NMTR) is set to execute a 1-for-20 reverse stock split, effective Oct. 17 5:00 p.m. ET. The company will begin trading on a split-adjusted basis from Oct. 18 under the existing ticker symbol NMTR. The move, which reduces the number of issued and outstanding common shares from 259,107,380 to ~12,955,369, is likely to bring the company into compliance with Nasdaq's minimum bid price requirement. The reverse stock split was previously approved by the company's shareholders at the Jun. 22 annual meeting. The split is not expected to alter any stockholder's percentage interest in the company's equity. NMTR shares were trading -4.53% pre-market. Source: Press Release
Price Target Changed • Sep 27Price target increased to US$3.40Up from US$3.00, the current price target is an average from 6 analysts. New target price is 1,487% above last closing price of US$0.21. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.17 next year compared to a net loss per share of US$0.15 last year.
Seeking Alpha • Aug 159 Meters Biopharma GAAP EPS of -$0.04 in-line9 Meters Biopharma press release (NASDAQ:NMTR): Q2 GAAP EPS of -$0.04 in-line. As of June 30, 2022, the company's cash and cash equivalents totaled approximately $29.5M, compared to approximately $37.2M as of March 31, 2022.
Price Target Changed • Jun 21Price target decreased to US$3.33Down from US$4.33, the current price target is an average from 6 analysts. New target price is 1,049% above last closing price of US$0.29. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$0.17 next year compared to a net loss per share of US$0.15 last year.
Recent Insider Transactions • May 20Independent Chairman recently bought US$50k worth of stockOn the 18th of May, Mark Sirgo bought around 106k shares on-market at roughly US$0.47 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$56k. Mark has been a buyer over the last 12 months, purchasing a net total of US$293k worth in shares.
Board Change • Apr 27High number of new and inexperienced directorsThere are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. 1 experienced director. No highly experienced directors. Independent Director Lorin Johnson is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • Mar 06President recently bought US$56k worth of stockOn the 3rd of March, John Temperato bought around 100k shares on-market at roughly US$0.56 per share. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of US$134k worth in shares.
Price Target Changed • Jan 26Price target decreased to US$4.33Down from US$4.92, the current price target is an average from 5 analysts. New target price is 478% above last closing price of US$0.75. Stock is down 37% over the past year. The company is forecast to post a net loss per share of US$0.15 next year compared to a net loss per share of US$0.58 last year.
Recent Insider Transactions • Nov 21President recently bought US$53k worth of stockOn the 18th of November, John Temperato bought around 50k shares on-market at roughly US$1.05 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$100k. John has been a buyer over the last 12 months, purchasing a net total of US$79k worth in shares.
Recent Insider Transactions • Nov 21President recently bought US$53k worth of stockOn the 18th of November, John Temperato bought around 50k shares on-market at roughly US$1.05 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$100k. John has been a buyer over the last 12 months, purchasing a net total of US$79k worth in shares.
Recent Insider Transactions • Sep 09Independent Chairman recently bought US$100k worth of stockOn the 7th of September, Mark Sirgo bought around 74k shares on-market at roughly US$1.36 per share. This was the largest purchase by an insider in the last 3 months. Mark has been a buyer over the last 12 months, purchasing a net total of US$224k worth in shares.
Executive Departure • Jun 26Director Sandeep Laumas has left the companyOn the 22nd of June, Sandeep Laumas was replaced as CEO by John Temperato after 1.2 years in the role. As of March 2021, Sandeep still personally held 60.40k shares (US$71k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.92 years, which is considered inexperienced in the Simply Wall St Risk Model. Under Sandeep's leadership, the company delivered a total shareholder return of -63%.
Breakeven Date Change • May 15Forecast to breakeven in 2024The 3 analysts covering 9 Meters Biopharma expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$15.1m in 2024. Average annual earnings growth of 60% is required to achieve expected profit on schedule.
Executive Departure • Feb 17Independent Director has left the companyOn the 12th of February, Nissim Darvish's tenure as Independent Director ended after less than a year in the role. We don't have any record of a personal shareholding under Nissim's name. A total of 4 executives have left over the last 12 months.
Is New 90 Day High Low • Feb 02New 90-day high: US$1.50The company is up 128% from its price of US$0.66 on 03 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$33.37 per share.
Is New 90 Day High Low • Jan 07New 90-day high: US$1.37The company is up 69% from its price of US$0.81 on 08 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$29.56 per share.
Is New 90 Day High Low • Nov 17New 90-day high: US$0.89The company is up 6.0% from its price of US$0.84 on 19 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 03New 90-day high: US$0.85The company is up 33% from its price of US$0.64 on 02 July 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.